The standard of symposia submissions was exceptionally high this year and the selection process very challenging. We have therefore, exceptionally, invited ten further groups to present their work in 60-minute colloquia.
We believe that the programme below showcases global research of the highest quality across a comprehensive range of topics.
SELECTED SYMPOSIA
5HT7 and 5HT4 Receptor Systems as Therapeutic Targets in Mood Disorders: What is New?
P. Stokes, L. Yatham, V. Frokjae
Psychedelics: From Bench to Clinic
G. Gobbi, B. Lerer, H. Tani
Susceptibility in the Developing Brain: Why the Timing of Insults and Sex Matter
M.-E. Tremblay, A. Grace, F. Gomes
Modulating the brain with light, sound and electric fields - the future of non-invasive brain stimulation in psychiatry?
L. Ustohal, G. Kranz, M.T. Ferretti
Adversity and altered states? The neurobiological signature of early life adversity on the brain, and relevance to psychoactive drug responses
E.E. Hisey, M. Carlyle, C.J. Morgan
Reformulation, omics-based biomarkers and health economic implications of ketamine in the treatment of depression
P. Glue, B. Baune, M.L. Chatterton
Moving Backward: From Treatment to Prevention in PTSD, Harnessing Neuroscience, Psychology, and Digital Tools
I. Galatzer -Levy, E. Vermetten, M. O'Donnel
Update on the Clinical Utility of PsychoPharmacogenetics
C. Bousman, M. Hopwood, R. van Westrhenen
From Molecular Mechanisms to Brain Circuitries: How Psychedelics are Reshaping Our Understanding of Neuropsychiatric and Behavioral Disorder Treatments
A. Aguilar-Valles, C. Foldi, D. De Gregorio
Pre- and postnatal maternal health and child outcomes
T. Halldorsdottir, J. Pestana, C. Cruceanu
New roles for neuromodulation in cognitive function and related disorders
S. Kida, B. Balleine, A. Holmes
The Role of Biomarkers in The Development of More Personalized and Effective Treatments for Psychiatric Disorders
M. de Rozario, M. Haaf, L. Han
Genetic Insights into Individual Variability in the Effects of Addictive Substances
J. Gelernter, A. Topiwala, D. Nishizawa
Neural Circuits of Dorsal Striatum and Amygdala in Addictive Behaviors
D.-S. Choi, A. Citri, J.-H. Baik
Adult neurogenesis or de-differentiation regulate hippocampus plasticity in health and disease
N. Abrous, T. Miyakawa, M. Boldrini
Muscarinic M1 and M4 receptors: Drug development, a treatment for schizophrenia and a potential treatment for addiction
C. Jones, B. Dean, M. Thomsen
Connecting the Dots in Opioid Addiction: Brain Circuits, Stress, and Clinical Trials
M. Creed, L. Mayo, T. Trang
Neurodevelopmental Disorder Models and Mechanisms
N. Hiroi, V. Tucci, T. Kikkawa
SELECTED COLLOQUIA
Effects of Early Life Adversity on the Structure of Common Mental Disorders: Reimagining the Diathesis-Stress Model
R. Krueger, F. Mann, M. Leyton
Promises and Pitfalls of Clinical Trial Design: How can we better evaluate novel target antipsychotics?
I. Khadimallah, P. McGorry, A. Grace
Adverse events: a neglected area in pharmacotherapeutics
G. Gobbi, S. Kasper, K. Fountoulakis
Targeting NMDA Receptors Mediate Neuron-Glia Interactions for the Treatment of Neuropsychiatric Disorders: From Basic Research to Application
S. Koizumi, J. Park, T. Soga
Circuits driving drug taking: What insights for treatment do they hold?
P. Kenny, L. Walker, M. James
Precision Psychiatry CINP GNC symposium: From biomarker discovery to therapeutic innovation toward personalized mental health care
D. Rujescu, S. Comai, B. Baune
Translational Approach to predict and accelerate Neuromodulation outcomes
S. Pallanti, P.B. Fitzgerald, V. Voon
Re-Evaluating 'Older' Drugs for the Treatment of Mood Disorders; a Focus on MAOI's, Lithium and Psychedelics
A. Young, P. Stokes, J. Rybakowski
Lithium: the latest news about the oldest drug in psychiatry
T. Hajek, D. Cousins, A. Young
Recent Advances in Obsessive Compulsive Disorder (OCD)
M. Warrier, J. Narayanaswamy, J. Zohar